Therapeutic-dose anticoagulation primarily consisting of rivaroxaban (Xarelto; Bayer/Janssen), compared with standard thromboprophylaxis, does not improve outcomes in patients hospitalized with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback